Insulin degludec/insulin aspart
Combination of | |
---|---|
Insulin degludec | Long-acting human insulin analog |
Insulin aspart | Fast-acting human insulin analog |
Clinical data | |
Trade names | Ryzodeg |
AHFS/Drugs.com | Professional Drug Facts |
License data | |
Pregnancy category | |
Routes of administration | Subcutaneous injection |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
CAS Number | |
KEGG |
Insulin degludec/insulin aspart, sold under the brand name Ryzodeg, is a fixed-dose combination medication for the treatment of diabetes mellitus.[3] It contains insulin degludec and insulin aspart.[3] It is given as an injection under the skin in the abdominal wall (at the front of the waist), upper arm or thigh.[3]
The most frequently reported side effect is hypoglycemia (low blood glucose levels).[3]
It was approved for medical use in the European Union in January 2013,[3] and in Australia in November 2017.[2]
Medical uses
Insulin degludec/insulin aspart is indicated for the treatment of diabetes mellitus in adults, adolescents and children from the age of two years.[3]
Insulin degludec and insulin aspart are slightly different from human insulin.[3] The differences mean that insulin degludec is absorbed more slowly by the body.[3] This means it has a long duration of action.[3] Meanwhile, insulin aspart is absorbed faster by the body than human insulin, and therefore it starts to work as soon as it is injected and has a short duration of action.[3]
References
- ↑ "Insulin aspart / insulin degludec (Ryzodeg 70/30) Use During Pregnancy". Drugs.com. 30 June 2020. Retrieved 26 July 2020.
- 1 2 3 "Ryzodeg 70/30 FlexTouch and Penfill (insulin degludec/insulin aspart) solution" (PDF). Novo Nordisk Pharmaceuticals Pty Ltd.
- 1 2 3 4 5 6 7 8 9 10 11 "Ryzodeg EPAR". European Medicines Agency (EMA). Retrieved 18 July 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
External links
- "Insulin aspart mixture with insulin degludec". Drug Information Portal. U.S. National Library of Medicine.
- Australian Public Assessment Report for insulin degludec (rys)/insulin aspart (rys) (PDF) (Report). Therapeutic Goods Administration (TGA).